Valanx GmbH

Valanx GmbH

VALANX is developing new approaches for bioconjugation. The products of this process, the bioconjugates, are needed to produce particularly specific drugs, special diagnostics or biosensors. VALANX supplies special compounds that react quickly and are cost-effective in order to produce targeted and specific conjugates. With its revolutionary technology, VALANX promises to make the conjugates usable as a tool for completely new industrial applications.

Investment date

March 2020

Industry sector

Biotechnology

Want to see more investments?